Corbus Pharmaceuticals (CRBP) vs Stablecoin Development (SDEV)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Corbus Pharmaceuticals (CRBP) has outperformed Stablecoin Development (SDEV) over the past year, losing 60.7% versus a loss of 66.8%. Over five years, CRBP leads with a -82.8% price change compared with -99.9% for SDEV. Stablecoin Development is the larger company by market cap ($103.0 million vs $101.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRBP | SDEV |
|---|---|---|
| Share price | $5.27 | $1.99 |
| Market cap | $101.93M | $102.99M |
| 1-day change | -4.01% | -28.42% |
| YTD return | -35.26% | -92.94% |
| 1-year return | -60.73% | -66.83% |
| 5-year return | -82.78% | -99.94% |
| EPS (TTM) | $-5.86 | $-21.13 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $20.56 | $99.75 |
| 52-week low | $5.13 | $0.78 |
| Distance from 52-week high | -74.37% | -98.01% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +545.73% | — |
| Average volume | 756.54K | 11.74M |
| Shares outstanding | 19.34M | 51.75M |
| Employees | 36 | 2 |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- The two companies sit in different sectors: Corbus Pharmaceuticals in Healthcare and Stablecoin Development in Health Care.
About Corbus Pharmaceuticals
CRBP stock →Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity.
Healthcare · Biotechnology · 36 employees
About Stablecoin Development
SDEV stock →Stablecoin Development Corporation engages in the accumulation and holding of digital assets for participation in blockchain-based networks. The company focuses on the accumulation, holding, and deployment of SKY, a protocol token of the decentralized Sky Protocol.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
CRBP vs SDEV FAQ
Which is bigger, Corbus Pharmaceuticals or Stablecoin Development?
Stablecoin Development (SDEV) is larger, with a market capitalization of $102.99M compared with $101.93M for Corbus Pharmaceuticals (CRBP).
Which stock has performed better over the past year, CRBP or SDEV?
CRBP returned -60.73% over the past 12 months, compared with -66.83% for SDEV (price return, excluding dividends). Past performance does not predict future results.
Are Corbus Pharmaceuticals and Stablecoin Development in the same industry?
No. Corbus Pharmaceuticals is in the Healthcare sector, while Stablecoin Development is in Health Care.